Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin in Minimal Hepatic Encephalopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-65 years~* Cirrhosis diagnosed on clinical grounds~* MHE diagnosed by abnormalities in a psychometric battery (NCT-A, NCT-B, ICT BDT and DST impaired beyond 2 standard deviations of known control values on any of the above 3 tests will be considered to have MHE)~* Current drivers (valid driving license and driving at least 20 miles/week)~* All women of child-bearing potential will be required to use effective contraception~Exclusion Criteria:~* Current or recent (\< 6 month) use of alcohol (AUDIT questionnaire will be used; any cirrhotic with a value of \> 0 will be excluded) and a positive blood alcohol level~* Use of antibiotics within last 6 weeks~* Allergy to rifaximin, rifabutin, rifampin, or rifapentine~* Infection or gastrointestinal hemorrhage within the last 6 weeks~* Renal insufficiency~* Hepatocellular carcinoma~* Psychoactive drug use, including interferon concurrently~* Non-drivers and those who drive less than 20 miles/week~* Pregnancy and breastfeeding~* Excluding patients with OHE:~  * Detailed neurological examination to check for dysarthria, asterixis, ataxia and disorientation~ * Detailed history-taking from friends/relatives only after taking the patient's permission~ * Mini-mental status examination \> 25~ * Episode of overt (clinical hepatic encephalopathy) within 6 months~ * Current treatment with lactulose, rifaximin, zinc, or metronidazole

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Will be given placebo and follow the exact procedures as the experimental section
- Drug (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).